TransCon CNP + Placebo for TransCon CNP
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Achondroplasia
Conditions
Achondroplasia
Trial Timeline
Jun 24, 2020 → Oct 1, 2024
NCT ID
NCT04085523About TransCon CNP + Placebo for TransCon CNP
TransCon CNP + Placebo for TransCon CNP is a phase 2 stage product being developed by Ascendis Pharma for Achondroplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT04085523. Target conditions include Achondroplasia.
What happened to similar drugs?
0 of 3 similar drugs in Achondroplasia were approved
Approved (0) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05598320 | Phase 2/3 | Completed |
| NCT05246033 | Phase 2 | UNKNOWN |
| NCT04085523 | Phase 2 | Completed |
Competing Products
20 competing products in Achondroplasia